What are you looking for?
Seoul, South Korea – October 2-4, 2024
Landing Med’s Chief Technology Officer (CTO), Dr. Pang Baochuan, was invited to speak at the inaugural Asia Society of Digital Pathology Congress in Seoul, South Korea, from October 2-4, 2024. As the only invited speaker from a Chinese company, Dr. Pang shared insights into Landing Med's pioneering technology behind its large-scale cervical cancer screening program and its impressive epidemiological results, which have garnered widespread attention for their transformative impact on early cancer detection in China.
The Asia Society of Digital Pathology Congress, a premier gathering of pathology experts, technologists, and innovators from around the world, provided a unique platform for thought leaders to explore the future of digital pathology, artificial intelligence (AI) in diagnostics, and the integration of cutting-edge technologies to enhance healthcare delivery.
During his presentation, Dr. Pang highlighted how Landing Med's AI-driven platform has revolutionized cervical cancer screening at scale, enabling high quality, affordable, and scalable screening solutions in China. The platform uses advanced AI algorithms to analyze cervical cytology samples, drastically improving screening efficiency and accuracy in areas where traditional methods, such as manual microscopy, are often limited by a shortage of trained pathologists.
The company’s large-scale cervical cancer screening program has been successfully deployed in China and achieved high screening coverage in remote regions. By leveraging AI, Landing Med has been able to significantly reduce the time and cost of screening while also improving the quality of results, ultimately leading to earlier detection and better outcomes for women in underserved regions.
“Cervical cancer is a major global health threat, especially in countries with limited access to medical resources,” said Dr. Pang Baochuan. “At Landing Med, we are committed to democratizing access to early cancer screening solutions. Our AI-driven screening platform not only increases efficiency but also addresses the critical shortage of pathologists. We believe that AI-powered pathology has the potential to transform the way we tackle preventable cancers globally.”
